The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Oral combination of HMAs + venetoclax in unfit or elderly patients with AML
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the combination of hypomethylating agents (HMA) with venetoclax in elderly and unfit patients with acute myeloid leukemia (AML), commenting on the benefits of an all-oral treatment regimen in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz
